• Abstract
• Full-Text PDF [623 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Shahinas, D
• Folefoc, A
• Pillai, DR.
• [+] on Google Scholar
• Shahinas, D
• Folefoc, A
• Pillai, DR.
• [+] on PubMed
• Shahinas, D
• Folefoc, A
• Pillai, DR.

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Pathogens 2013, 2(1), 33-54; doi:10.3390/pathogens2010033

Review

Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance

Dea Shahinas ¹ , Asongna Folefoc ^2,3  and Dylan R. Pillai ^2,3,*

¹ Department of Laboratory Medicine & Pathobiology, University of Toronto, Canada ² Department of Pathology & Laboratory Medicine, The University of Calgary, Calgary, AB, Canada ³ Department of Microbiology, Immunology, and Infectious Diseases, The University of Calgary, Diagnostic & Scientific Centre, Room 1W-416, 9-3535 Research Road NW, Calgary, AB T2L 2K8, Canada

* Author to whom correspondence should be addressed.

Received: 8 December 2012; in revised form: 18 January 2013 / Accepted: 23 January 2013 / Published: 4 February 2013

(This article belongs to the Special Issue Host-Parasite Interactions)

Download PDF Full-Text [623 KB, uploaded 4 February 2013 16:10 CET]

Abstract: Malaria continues to exact a great human toll in tropical settings. Antimalarial resistance is rife and the parasite inexorably develops mechanisms to outwit our best drugs, including the now first-line choice, artesunate. Novel strategies to circumvent resistance are needed. Here we detail drug development focusing on heat shock protein 90 and its central role as a chaperone. A growing body of evidence supports the role for Hsp90 inhibitors as adjunctive drugs able to restore susceptibility to traditionally efficacious compounds like chloroquine.

Keywords: malaria; hsp90; antimalarial resistance

Article Statistics

Cite This Article